Myotonic Disorders: Clinical Trials

21 trials for Myotonic Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 5 recruiting, 2 active not recruiting, 2 enrolling by invitation. 21 Phase 2, 8 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 221Completed 12, Recruiting 5, Active not recruiting 2, Enrolling by invitation 2
Phase 18Completed 3, Active not recruiting 2, Recruiting 2, Enrolling by invitation 1
Phase 34Completed 3, Recruiting 1

Follow Myotonic Disorders: new trials by email Literature Review of Myotonic Disorders trials Research Report on Myotonic Disorders

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
PGN-EDODM1 - Myotonic Dystrophy 1
Phase 2RecruitingPepGen Inc482025-12-232026-03-30
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
SAR446268 - Myotonic Dystrophy
Phase 1 / Phase 2RecruitingSanofi322025-07-232026-09-21
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
VX-670 - Myotonic Dystrophy Type 1 (DM1)
Phase 2Enrolling by invitationVertex Pharmaceuticals Incorporated442025-04-282026-10-14
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
PGN-EDODM1, Placebo - Myotonic Dystrophy 1
Phase 2RecruitingPepGen Inc242024-12-102026-07-29
Study of ATX-01 in Participants With DM1
ATX-01, Placebo - Myotonic Dystrophy 1
Phase 1 / Phase 2RecruitingARTHEx Biotech S.L.562024-10-152026-02-10
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
SRP-1003 IV Infusion, Placebo IV Infusion, SRP-1003 SC Injection - Myotonic Dystrophy 1
Phase 1 / Phase 2Enrolling by invitationSarepta Therapeutics, Inc.782024-03-042026-10-05
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
VX-670, Placebo - Myotonic Dystrophy Type 1 (DM1)
Phase 1 / Phase 2Active not recruitingVertex Pharmaceuticals Incorporated472024-02-202026-08-20
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
DYNE-101, Placebo - Myotonic Dystrophy Type 1 (DM1)
Phase 1 / Phase 2Active not recruitingDyne Therapeutics1272022-09-052026-09-23
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Placebo, AOC 1001 - DM1, Muscular Dystrophies
Phase 2CompletedAvidity Biosciences, Inc.372022-08-042026-09-11
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001, Placebo - DM1, Myotonic Dystrophy 1
Phase 1 / Phase 2CompletedAvidity Biosciences, Inc.392021-10-282026-09-28
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Tideglusib - Congenital Myotonic Dystrophy
Phase 2 / Phase 3RecruitingAMO Pharma Limited762021-08-232025-05-28
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
Pitolisant Oral Tablet, Placebo oral tablet - Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Phase 2CompletedHarmony Biosciences Management, Inc.302021-06-282026-09-04
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Tideglusib, Placebo - Congenital Myotonic Dystrophy
Phase 2 / Phase 3CompletedAMO Pharma Limited562021-03-032025-10-08
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
Tideglusib - Myotonic Dystrophy 1
Phase 2CompletedAMO Pharma Limited162016-07-202025-09-11
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
IONIS-DMPKRx, Placebo - Myotonic Dystrophy Type 1
Phase 1 / Phase 2CompletedIonis Pharmaceuticals, Inc.482014-12-012022-12-06
Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)
Mexiletine, Placebo - Non Dystrophic Myotonia
Phase 2CompletedRadboud University Medical Center302014-01-012016-01-26
Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Mexiletine, Placebo - Myotonic Dystrophy
Phase 2CompletedUniversity of Rochester422011-06-012018-06-19
Methylphenidate in Myotonic Dystrophy Type 1
Methylphenidate, Placebo - Dystrophia Myotonica 1
Phase 2 / Phase 3CompletedLaval University282008-06-012011-08-23
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
rhIGF-I/rhIGFBP-3, placebo - Myotonic Dystrophy Type 1
Phase 2CompletedInsmed Incorporated692007-12-012022-01-06
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
SomatoKine/IPLEX - Myotonic Dystrophy
Phase 1 / Phase 2CompletedUniversity of Rochester172005-11-012012-06-25

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Myotonic Dystrophy (20)  ·  Neuromuscular Diseases (5)  ·  Genetic Diseases, Inborn (4)  ·  Heredodegenerative Disorders, Nervous System (4)  ·  Muscular Diseases (4)  ·  Muscular Disorders, Atrophic (4)  ·  Muscular Dystrophies (4)  ·  Musculoskeletal Diseases (4)  ·  Nervous System Diseases (4)  ·  Disorders of Excessive Somnolence (3)  ·  Neurodegenerative Diseases (3)  ·  Myotonia (2)  ·  Potassium aggravated myotonia (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20)  ·  Muscular Diseases (17)  ·  Musculoskeletal Diseases (17)  ·  Nervous System Diseases (17)  ·  Neurodegenerative Diseases (17)  ·  Genetic Diseases, Inborn (16)  ·  Heredodegenerative Disorders, Nervous System (16)  ·  Muscular Disorders, Atrophic (16)  ·  Muscular Dystrophies (16)  ·  Neuromuscular Diseases (16)  ·  Dyssomnias (3)  ·  Mental Disorders (3)  ·  Sleep Disorders, Intrinsic (3)  ·  Sleep Wake Disorders (3)

Interventions

tideglusib (3)  ·  Mexiletine (2)  ·  IGF-I-IGFBP-3 complex (1)  ·  Insulin-Like Growth Factor I (1)  ·  Methylphenidate (1)  ·  Sodium Chloride (1)  ·  pitolisant (1)  ·  somatoKine (1)

Sponsors

AMO Pharma Limited (3)  ·  Avidity Biosciences, Inc. (2)  ·  PepGen Inc (2)  ·  University of Rochester (2)  ·  Vertex Pharmaceuticals Incorporated (2)  ·  ARTHEx Biotech S.L. (1)  ·  Dyne Therapeutics (1)  ·  Harmony Biosciences Management, Inc. (1)  ·  Insmed Incorporated (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  Laval University (1)  ·  Radboud University Medical Center (1)  ·  Sanofi (1)  ·  Sarepta Therapeutics, Inc. (1)  ·  University of Versailles (1)

Countries

United States (14)  ·  Canada (11)  ·  United Kingdom (9)  ·  Australia (7)  ·  France (5)  ·  Netherlands (5)  ·  New Zealand (5)  ·  Germany (4)  ·  Italy (4)  ·  Spain (4)  ·  Belgium (3)  ·  Argentina (1)  ·  Israel (1)  ·  South Korea (1)  ·  Taiwan (1)

Top investigators

Dr. G Drost, MD, PhD (1)  ·  Drs. B Schouwenberg, MD (1)  ·  Drs. BC Stunnenberg, MD (1)  ·  Drs. H Groenewoud, MSc (1)  ·  Drs. J Raaphorst, MD (1)  ·  Drs. J Timmermans, MD (1)  ·  Drs. N van Alfen, MD, PhD (1)  ·  Drs. W Woertman, PhD (1)  ·  Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP (1)  ·  Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM (1)  ·  Jack J Puymirat, MD (1)  ·  Joseph P Horrigan, MD (1)  ·  Li Tai, MD (1)

Results publications

PMID 18678823, PMID 20837825, PMID 22578232, PMID 25880166, PMID 30535218, PMID 32942085, PMID 36790141, PMID 36804094, PMID 39555632, PMID 41707138

NIH funding

2016 (2), 2023 (2), U54NS048843 (1)